DF6215

DF6215 is a modified, monovalent recombinant human interleukin-2 (IL-2) cytokine engineered to selectively activate the IL-2 receptor. It is designed as an IL-2Rα-active agonist with increased stimulation of the IL-2Rβγ subunits, aiming to enhance anti-tumor immune responses by promoting expansion and activation of cytotoxic CD8+ T cells and natural killer (NK) cells while minimizing regulatory T cell (Treg) expansion. The molecule incorporates an Fc fusion for prolonged half-life, allowing less frequent dosing compared to earlier IL-2 therapies. Preclinical studies demonstrated that DF6215 produces sustained pharmacodynamic effects and robust anti-tumor activity without inducing capillary leak syndrome or cytokine release syndrome in animal models. It is currently being evaluated in Phase 1/1b clinical trials for patients with advanced solid tumors, including melanoma, renal cell carcinoma, non-small-cell lung cancer, ovarian cancer, head and neck cancer, and HPV-positive malignancies[2][3][4][5][6][7][8].

Other names

Interleukin-2 Fc fusion proteinInterleukin2 Fc fusion proteinInterleukin 2 Fc fusion proteinIL-2-Fc fusion proteinIL2-Fc fusion proteinIL 2-Fc fusion protein